Butterfly Pea
Generic Name: butterfly pea
Brand Names:
T-42
Temporary relief of symptoms associated with feeling disconnected emotionally and mentally from others and from community.
Overview
Temporary relief of symptoms associated with feeling disconnected emotionally and mentally from others and from community.
Uses
INDICATIONS Temporary relief of symptoms associated with feeling disconnected emotionally and mentally from others and from community.
Dosage
One dropper under tongue two times daily. Acute symptoms 1/2 dropper under tongue every 30 minutes for two hours.
Warnings
Use only if cap seal is unbroken. If pregnant or breastfeeding, ask a healthcare professional before use. Keep this and all medication out of the reach of children.
Pregnancy
If pregnant or breastfeeding, ask a healthcare professional before use.
Storage
SHAKE WELL
Frequently Asked Questions
What is Butterfly Pea used for?▼
INDICATIONS Temporary relief of symptoms associated with feeling disconnected emotionally and mentally from others and from community.
Can I take Butterfly Pea during pregnancy?▼
If pregnant or breastfeeding, ask a healthcare professional before use.
What are the important warnings for Butterfly Pea?▼
Use only if cap seal is unbroken. If pregnant or breastfeeding, ask a healthcare professional before use. Keep this and all medication out of the reach of children.
Related Medications
Alpha Lipoic Acid, Arnica Montanaroot,sus Scrofa Cartilage,coenzyme A, Solanum Dulcamara Top, Sus Scrofa Embryo,sus Scrofa Umbilical Cord,nadide,sodium Diethyl Oxalacetate, Sus Scrofa Placenta,toxicodendron Pubescens Leaf,sanguinaria Canadensis Root,silicon Dioxide,sulfur,comfrey Root
alpha lipoic acid, arnica montanaroot,sus scrofa cartilage,coenzyme a, solanum dulcamara top, sus scrofa embryo,sus scrofa umbilical cord,nadide,sodium diethyl oxalacetate, sus scrofa placenta,toxicodendron pubescens leaf,sanguinaria canadensis root,silicon dioxide,sulfur,comfrey root
Dosage form: TABLET. Active ingredients: ALPHA LIPOIC ACID (6 [hp_X]/1); ARNICA MONTANA ROOT (1 [hp_X]/1); COENZYME A (6 [hp_X]/1); COMFREY ROOT (8 [hp_X]/1); NADIDE (6 [hp_X]/1); SANGUINARIA CANADENSIS ROOT (3 [hp_X]/1); SILICON DIOXIDE (6 [hp_X]/1); SODIUM DIETHYL OXALACETATE (6 [hp_X]/1); SOLANUM DULCAMARA TOP (2 [hp_X]/1); SULFUR (6 [hp_X]/1); SUS SCROFA CARTILAGE (4 [hp_X]/1); SUS SCROFA EMBRYO (4 [hp_X]/1); SUS SCROFA PLACENTA (4 [hp_X]/1); SUS SCROFA UMBILICAL CORD (4 [hp_X]/1); TOXICODEN
Babesia Microti, Babesia Microti Dna
babesia microti, babesia microti dna
Dosage form: LIQUID. Active ingredients: BABESIA MICROTI (10 [hp_M]/mL); BABESIA MICROTI DNA (10 [hp_M]/mL). Category: DRUG FOR FURTHER PROCESSING.
Canakinumab
canakinumab
11 DESCRIPTION Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298).
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.